Tm Bioscience to supply ARUP Laboratories with Tag-It™ P450 Tests
News Oct 13, 2005
Tm Bioscience Corporation has announced it has signed an agreement to supply ARUP Laboratories with Tag-It™ P450 Drug Metabolism tests.
ARUP previously presented results of a drug metabolism study based on genotyping data obtained using the P450 test from Tm Bioscience.
In a poster presented at the American College of Medical Genetics' 2005 Annual Clinical Genetics Meeting entitled "CYP2D6, CYP2C9 and CYP2C19 genotyping of Venlafaxine (Effexor) treated patients, seeking correlation between genotype and metabolic phenotype," researchers from ARUP describe how drug metabolism associated genes were assessed in patients by using the suite of P450 assays from Tm Bioscience.
"Individuals metabolize medicines at different rates. The P450 tests from Tm were used to perform a clinical study that correlated genetic profiles of patients with the amount of an active antidepressant drug present in their blood," said Dr. Gwen McMillin, an assistant professor of Pathology at the University of Utah and medical director of the Clinical Toxicology and Trace Elements Laboratories at ARUP.
"The results we generated demonstrate the potential value of conducting genetic screening to help determine the metabolic profile of patients, which could improve the ability of physicians to optimize drug and dose selection. This type of testing brings us one step closer to personalized medicine."
"ARUP is one of the leading national reference laboratories, serving a broad range of customers across the U.S.," said Greg Hines, President and CEO of Tm Bioscience.
"We are delighted that ARUP has selected our Tag-It™ technology and look forward to working with them to adopt additional products from Tm."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.